Isoniazid: An update on the multiple mechanisms for a singular action

Current Medicinal Chemistry

Volumn 20, Issue 35, 2013, Pages 4370-4385

  Bernardes Genisson V ^a,b   Deraeve, C ^a,b   Chollet, A ^a,b   Bernadou, J ^a,b   Pratviel, G ^a,b  

^a LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Isoniazid; Isoniazid resistances; KatG; Mechanism of action; Mycobacterium tuberculosis; Pro drug; Radicals

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; AUTOOXIDATION; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANT TUBERCULOSIS; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; HUMAN; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84887928420     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/15672050113109990203     Document Type: Article

References (121)

1. http://www.who.int/gho/tb/epidemic/cases-deaths/en/index.html
2. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393(6685), 537-544.
3. Lee, R.E.; Brennan, P.J.; Besra, G.S. Mycobacterium tuberculosis cell envelope. Curr. Top. Microbiol. Immunol., 1996, 215, 1-27.
4. Asselineau, J. Sur la structure chimique des acides mycoliques isolés de Mycobacterium tuberculosis var. hominis; détermination de la position de l'hydroxyle. C.R. Hebd. Seances Acad. Sci., 1950, 230, 1620-1622.
5. Scior, T.; Meneses Morales, I.; Garcés Eisele, S.J.; Domeyer, D.; Laufer, S. Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis-A Review. Arch. Pharm. Pharm. Med. Chem., 2002, 335(11-12), 511-525.
6. World Health Organisation, Treatment of Tuberculosis: guidelines for national programmes 2011, http://who.int/tb/publications/ cds-tb-2003-2313/en/ index.html.
7. Meyer, H.; Mally, J. Über Hydrazinderivate der Pyridincarbonsä uren. Monatsh. Chem., 1912, 33(4), 393-414.
8. Gardner, T.S.; Smith, F.A.; Wenis, E.; Lee, J. The Synthesis of Compounds for the Chemotherapy of Tuberculosis. VI. Hydrazine Derivatives. J. Org. Chem., 1956, 21(5), 530-533.
9. Seydel, J.K.; Schaper, K.J.; Wempe, E.; Cordes, H.P. Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type. J. Med. Chem., 1976, 19(4), 483-492.
10. Popli, S.P.; Dhar, M.L. Studies in potential antimycobacterial agents : Part V-Synthesis of some 4-hydroxy-3-quinolyl hydrazides & their derivatives. J. Sci. Industr. Res., 1955, 14B, 261-263.
11. Klopman, G.; Fercu, D.; Jacob, J. Computer-aided study of the relationship between structure and antituberculosis activity of a series of isoniazid derivatives. Chem. Phys., 1996, 204(2-3), 181-193.
12. Albert, A. The affinity of isonicotinic hydrazide for metals. Experientia, 1953, 9(10), 370.
13. Winder, F.G.; Denneny, J.M. Metal-catalysed auto-oxidation of isoniazid. Biochem. J., 1959, 73(3), 500-507.
14. Albert, A. Mode of action of isoniazid. Nature, 1956, 177(4507), 525-526.
15. Preziosi, P. Isoniazid: Metabolic aspects and toxicological correlates. Curr. Drug Metab., 2007, 8(8), 839-851.
16. Youatt, J. A review of the action of isoniazid. Am. Rev. Resp. Dis., 1969, 99(5), 729-749.
17. Wayne, L.G.; Diaz, G.A.; Doubek, J.R. Acquired isoniazid resistance and catalase activity of myobacteria. Am. Rev. Resp. Dis., 1968, 97(5), 909-913.
18. Karakousis, P.C.; Williams, E.P.; Bishai, W.R. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J. Antimicrob. Chemoth., 2008, 61(2), 323-331.
19. Delaine, T.; Bernardes-Genisson, V.; Quemard, A.; Constant, P.; Cosledan, F.; Meunier, B.; Bernadou, J. Preliminary Investigations of the Effect of Lipophilic Analogues of the Active Metabolite of Isoniazid Toward Bacterial and Plasmodial Strains. Chem. Biol. Drug Des., 2012, 79(6), 1001-1006.
20. Zhang, Y.; Young, D.B. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. Trends Microbiol., 1993, 1(3), 109-113.
21. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992, 358(6387), 591-593.
22. Middlebrook, G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am. Rev. Tuberc., 1952, 65(6), 765-767.
23. Middlebrook, G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am. Rev. Tuberc., 1954, 69(3), 471-472.
24. Middlebrook, G.; Cohn, M.L.; Schaefer, W.B. Studies on isoniazid and tubercle bacilli. III. The isolation, drug-susceptibility, and catalase-testing of tubercle bacilli from isoniazid-treated patients. Am. Rev. Tuberc., 1954, 70(5), 852-872.
25. Haas, W.H.; Schilke, K.; Brand, J.; Amthor, B.; Weyer, K.; Fourie, P.B.; Bretzel, G.; StichtGroh, V.; Bremer, H.J. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother., 1997, 41(7), 1601-1603.
26. Wei, C.-J.; Lei, B.; Musser, J.M.; Tu, S.-C. Isoniazid Activation Defects in Recombinant Mycobacterium tuberculosis Catalase-Peroxidase (KatG) Mutants Evident in InhA Inhibitor Production. Antimicrob. Agents Chemother., 2003, 47(2), 670-675.
27. Bertrand, T.; Eady, N.A.J.; Jones, J.N.; Nagy, J.M.; Jamart-Gregoire, B.; Raven, E.L.; Brown, K.A. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J. Biol. Chem., 2004, 279(37), 38991-38999.
28. Zhao, X.B.; Yu, H.; Yu, S.W.; Wang, F.; Sacchettini, J.C.; Magliozzo, R.S. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Biochemistry, 2006, 45(13), 4131-4140.
29. Zhang, Y.; Garbe, T.; Young, D. Transformation with KatG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol., 1993, 8(3), 521-524.
30. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K.S.; Wilson, T.; Collins, D.; Delisle, G.; Jacobs, W.R. Inha, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 1994, 263(5144), 227-230.
31. Heym, B.; Cole, S.T. Les mécanismes moléculaires de la résistance de Mycobacterium tuberculosis aux antibiotiques. Med. Mal. Infect., 1996, 26(11), 926-929.
32. Rawat, R.; Whitty, A.; Tonge, P.J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Nat. Acad. Sci. USA, 2003, 100(24), 13881-13886.
33. Lee, A.S.G.; Teo, A.S.M.; Wong, S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother., 2001, 45(7), 2157-2159.
34. Cohen, T.; Sommers, B.; Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis., 2003, 3(1), 13-21.
35. Miesel, L.; Weisbrod, T.R.; Marcinkeviciene, J.A.; Bittman, R.; Jacobs, W.R. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol., 1998, 180(9), 2459-2467.
36. Guo, H.; Seet, Q.; Denkin, S.; Parsons, L.; Zhang, Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol., 2006, 55(11), 1527-1531.
37. Hazbón, M.H.; Brimacombe, M.; Bobadilla del Valle, M.; Cavatore, M.; Guerrero, M.I.; Varma-Basil, M.; Billman-Jacobe, H.; Lavender, C.; Fyfe, J.; García-García, L.; León, C.I.; Bose, M.; Chaves, F.; Murray, M.; Eisenach, K.D.; Sifuentes-Osornio, J.; Cave, M.D.; Ponce de León, A.; Alland, D. Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2006, 50(8), 2640-2649.
38. Machado, D.; Couto, I.; Perdigao, J.; Rodrigues, L.; Portugal, I.; Baptista, P.; Veigas, B.; Amaral, L.; Viveiros, M. Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis. Plos One, 2012, 7(4), e34538.
39. Beggs, W.H.; Jenne, J.W.; Hall, W.H. Isoniazid Uptake in Relation to Growth Inhibition of Mycobacterium tuberculosis. J. Bacteriol., 1968, 96(2), 293-297.
40. Barclay, W.R.; Ebert, R.H.; Kochweser, D. Mode of action of isoniazid. Am. Rev. Tuberc., 1953, 67(4), 490-496.
41. Barclay, W.R.; Koch-Weser, D.; Ebert, R.H. Mode of action of isoniazid. II. Am. Rev. Tuberc., 1954, 70(5), 784-792.
42. Tsukamura, M.; Tsukamura, S.; Nakano, E. The uptake of isoniazid by mycobacteria and its relation to isoniazid susceptibility. Am. Rev. Respir. Dis., 1963, 87, 269-275.
43. Wimpenny, J.W. The uptake and fate of isoniazid in Mycobacterium tuberculosis var. bovis BCG. J. Gen. Microbiol., 1967, 47(3), 389-403.
44. Youatt, J. The uptake of isoniazid by washed cell suspensions of Mycobacteria and other organisms. Aust. J. Exp. Biol., 1958, 36(3), 223-234.
45. McClatchy, J.K. Mechanism of Action of Isoniazid on Mycobacterium bovis Strain BCG. Infect. Immun., 1971, 3(4), 530-534.
46. Youatt, J. The uptake of isoniazid and related compounds by Mycobacteria. Aust. J. Exp. Biol., 1960, 38, 331-338.
47. Bardou, F.; Raynaud, C.; Ramos, C.; Lanéelle, M.A.; Lannéelle, G. Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology, 1998, 144(9), 2539-2544.
48. Hansch, C.; Leo, A.; Hoekman, D.H. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants. American Chemical Society Washington, D.C., 1995.
49. Sangster, J. In Fundamentals and Physical Chemistry; Wiley: Chichester, 1997.
50. Cymerman-Craig, J.; Willis, D.; Rubbo, S.D.; Edgar, J. Mode of action of isonicotinic hydrazide. Nature, 1955, 176(4470), 34-35.
51. Krivis, A.F.; Rabb, J.M. Cuprous complexes formed with isonicotinic hydrazide. Science, 1969, 164(3883), 1064-1065.
52. Hanson, J.C.; Camerman, N.; Camerman, A. Structure of a copperisoniazid complex. J. Med. Chem., 1981, 24(11), 1369-1371.
53. Srivastava, A. Antiviral Activity of Copper Complexes of Isoniazid against RNA Tumor Viruses. Resonance, 2009, 754-760.
54. Garg, A.; Samota, S.; Singh, M.; Pandey, R. Polarographic study of Cu(II)-Isoniazid complex at D.M.E. Int. J. Chem. Tech. Res., 2011, 3, 70-74.
55. Coleman, C.M. A proposed mode of action for isoniazid in the tubercle bacillus and other biological systems. Am. Rev. Tuberc., 1954, 89(6), 1062-1063.
56. Muakkassah, S.F.; Bidlack, W.R.; Yang, W.C.T. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochem. Pharm., 1981, 30(12), 1651-1658.
57. Sorkin, E.; Roth, W.; Erlenmeyer, H. Über die Beeinflussung tuberkulostatischer Wirkungen durch Cu. Metallionen und biologische Wirkung, 7. Mitteilung. Helv. Chim. Acta, 1952, 35(5), 1736-1741.
58. Youatt, J. The influence of copper on the uptake of hydrazides. Aust. J. Exp. Biol., 1962, 40, 201-206.
59. Rodriguez, G.M. Control of iron metabolism in Mycobacterium tuberculosis. Trends Microbiol., 2006, 14(7), 320-327.
60. Ratledge, C. Iron, mycobacteria and tuberculosis. Tuberculosis, 2004, 84(1-2), 110-130.
61. Botella, H.; Peyron, P.; Levillain, F.; Poincloux, R.; Poquet, Y.; Brandli, I.; Wang, C.; Tailleux, L.; Tilleul, S.; Charrière, G.M.; Waddell, Simon J.; Foti, M.; Lugo-Villarino, G.; Gao, Q.; Maridonneau-Parini, I.; Butcher, Philip D.; Castagnoli, Paola R.; Gicquel, B.; de Chastellier, C.; Neyrolles, O. Mycobacterial P1-Type ATPases Mediate Resistance to Zinc Poisoning in Human Macrophages. Cell. Host & Microbe., 2011, 10(3), 248-259.
62. Long, E.R. In The chemistry and chemotherapy of tuberculosis; William & Wilkins: Baltimore, 1958, pp 362-388.
63. Beggs, W.H.; Jenne, J.W. Mechanism for the pyridoxal neutralization of isoniazid action of Mycobacterium tuberculosis. J. Bacteriol., 1967, 94(4), 793-797.
64. Pope, H. The neutralization of isoniazid activity in Mycobacterium tuberculosis by certain metabolites. Am. Rev. Tuberc., 1956, 73(5), 735-747.
65. Quémard, A.; Lacave, C.; Lanéelle, G. Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum. Antimicrob. Agents Chemother., 1991, 35(6), 1035-1039.
66. Herman, R.P.; Weber, M.M. Isoniazid interaction with tyrosine as a possible mode of action of the drug in mycobacteria. Antimicrob. Agents Chemother., 1980, 17(2), 170-178.
67. Chouchane, S.; Lippai, I.; Magliozzo, R.S. Catalase-peroxidase (Mycobacterium tuberculosis KatG) catalysis and isoniazid activation. Biochemistry, 2000, 39(32), 9975-9983.
68. Saint-Joanis, B.; Souchon, H.; Wilming, M.; Johnsson, K.; Alzari, P.M.; Cole, S.T. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem. J., 1999, 338, 753-760.
69. Timmins, G.S.; Master, S.; Rusnak, F.; Deretic, V. Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo. J. Bacteriol., 2004, 186(16), 5427-5431.
70. Gangadharam, P.R.; Harold, F.M.; Schaefer, W.B. Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid. Nature, 1963, 198, 712-714.
71. Timmins, G.S.; Deretic, V. Mechanisms of action of isoniazid. Mol. Microbiol., 2006, 62(5), 1220-1227.
72. Wengenack, N.L.; Rusnak, F. Evidence for isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T). Biochemistry, 2001, 40, (30), 8990-8996.
73. Chan, J.; Xing, Y.; Magliozzo, R.S.; Bloom, B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med., 1992, 175(4), 1111-1122.
74. MacMicking, J.D.; North, R.J.; LaCourse, R.; Mudgett, J.S.; Shah, S.K.; Nathan, C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Nat. Acad. Sci. USA, 1997, 94(10), 5243-5248.
75. Timmins, G.S.; Master, S.; Rusnak, F.; Deretic, V. Nitric Oxide Generated from Isoniazid Activation by KatG: Source of Nitric Oxide and Activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2004, 48(8), 3006-3009.
76. Yu, K.; Mitchell, C.; Xing, Y.; Magliozzo, R.S.; Bloom, B.R.; Chan, J. Toxicity of nitrogen oxides and related oxidants on mycobacteria: M. tuberculosis is resistant to peroxynitrite anion. Tuber. Lung Dis., 1999, 79(4), 191-198.
77. Sipe, H.J.; Jaszewski, A.R.; Mason, R.P. Fast-flow EPR spectroscopic observation of isoniazid, iproniazid, and phenylhydrazine hydrazyl radicals. Chem. Res. Toxicol., 2004, 17(2), 226-233.
78. Ito, K.; Yamamoto, K.; Kawanishi, S. Manganese-mediated oxidative damage of cellular and isolated DNA by isoniazid and related hydrazines-non-fenton-type hydroxyl radical formation. Biochemistry, 1992, 31(46), 11606-11613.
79. Shoeb, H.A.; Bowman, B.U.; Ottolenghi, A.C.; Merola, A.J. Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother., 1985, 27(3), 404-407.
80. Ebina, T.; Motomiya, M.; Munakata, K.; Kobuya, G. Effect of isoniazid on fatty acids in Mycobacterium. C.R. Séances Soc. Biol. Ses. Fil. , 1961, 155, 1176-1178.
81. Brennan, P.J.; Rooney, S.A.; Winder, F.G. The lipids of Mycobacterium tuberculosis BCG: fractionation, composition, turnover and the effects of isoniazid. Irish J. Med. Sci., 1970, 3(8), 371-390.
82. Winder, F.G.; Collins, P.; Rooney, S.A. Effects of isoniazid on mycolic acid synthesis in Mycobacterium tuberculosis and on its cell envelope. Biochem. J., 1970, 117(2), 27.
83. Takayama, K.; Wang, L.; David, H.L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1972, 2(1), 29-35.
84. Rozwarski, D.A.; Grant, G.A.; Barton, D.H.R.; Jacobs, W.R.; Sacchettini, J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 1998, 279(5347), 98-102.
85. Lei, B.; Wei, C.-J.; Tu, S.-C. Action Mechanism of Antitubercular Isoniazid. J. Biol. Chem., 2000, 275(4), 2520-2526.
86. Dessen, A.; Quemard, A.; Blanchard, J.S.; Jacobs, W.R.; Sacchettini, J.C. Crystal-structure and function of the isoniazid target of Mycobacterium tuberculosis. Science, 1995, 267(5204), 1638-1641.
87. Winder, F.G.; Collins, P.B. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol., 1970, 63(1), 41-48.
88. Takayama, K.; Schnoes, H.K.; Armstrong, E.L.; Boyle, R.W. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res., 1975, 16(4), 308-317.
89. Vilcheze, C.; Weisbrod, T.R.; Chen, B.; Kremer, L.; Hazbon, M.H.; Wang, F.; Alland, D.; Sacchettini, J.C.; Jacobs, W.R. Altered NADH/NAD(+) ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents Chemother., 2005, 49(2), 708-720.
90. Nguyen, M.; Quemard, A.; Broussy, S.; Bernadou, J.; Meunier, B. Mn(III) Pyrophosphate as an Efficient Tool for Studying the Mode of Action of Isoniazid on the InhA Protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46(7), 2137-2144.
91. Wilming, M.; Johnsson, K. Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew. Chem. Int. Ed., 1999, 38(17), 2588-2590.
92. Stigliani, J.-L.; Arnaud, P.; Delaine, T.; Bernardes-Génisson, V.; Meunier, B.; Bernadou, J. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): A theoretical approach. J. Mol. Graph. Model., 2008, 27(4), 536-545.
93. Parikh, S.; Moynihan, D.P.; Xiao, G.; Tonge, P.J. Roles of Tyrosine 158 and Lysine 165 in the Catalytic Mechanism of InhA, the Enoyl-ACP Reductase from Mycobacterium tuberculosis. Biochemistry, 1999, 38(41), 13623-13634.
94. Parikh, S.L.; Xiao, G.P.; Tonge, P.J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry, 2000, 39(26), 7645-7650.
95. Broussy, S.; Bernardes-Genisson, V.; Coppel, Y.; Quemard, A.; Bernadou, J.; Meunier, B. 1H and 13C NMR characterization of pyridinium-type isoniazid-NAD adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Org. Biomol. Chem., 2005, 3(4), 670-673.
96. Mdluli, K.; Slayden, R.A.; Zhu, Y.; Ramaswamy, S.; Pan, X.; Mead, D.; Crane, D.D.; Musser, J.M.; Barry, C.E. Inhibition of a Mycobacterium tuberculosis-Ketoacyl ACP Synthase by Isoniazid. Science, 1998, 280(5369), 1607-1610.
97. Kremer, L.; Dover, L.G.; Morbidoni, H.R.; Vilchèze, C.; Maughan, W.N.; Baulard, A.; Tu, S.-C.; Honoré, N.; Deretic, V.; Sacchettini, J.C.; Locht, C.; Jacobs, W., R.; Besra, G.S. Inhibition of InhA Activity, but Not KasA Activity, Induces Formation of a KasAcontaining Complex in Mycobacteria. J. Biol. Chem., 2003, 278(23), 20547-20554.
98. Kremer, L.; Douglas, J.D.; Baulard, A.R.; Morehouse, C.; Guy, M.R.; Alland, D.; Dover, L.G.; Lakey, J.H.; Jacobs, W.R.; Brennan, P.J.; Minnikin, D.E.; Besra, G.S. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem., 2000, 275(22), 16857-16864.
99. Larsen, M.H.; Vilcheze, C.; Kremer, L.; Besra, G.S.; Parsons, L.; Salfinger, M.; Heifets, L.; Hazbon, M.H.; Alland, D.; Sacchettini, J.C.; Jacobs, W.R. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M-bovis BCG and M-tuberculosis. Mol. Microbiol., 2002, 46(2), 453-466.
100. Marrakchi, H.; Ducasse, S.; Labesse, G.; Montrozier, H.; Margeat, E.; Emorine, L.; Charpentier, X.; Daffé, M.; Quémard, A.k. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology, 2002, 148(4), 951-960.
101. Ducasse-Cabanot, S.; Cohen-Gonsaud, M.; Marrakchi, H.; Nguyen, M.; Zerbib, D.; Bernadou, J.; Daffé, M.; Labesse, G.; Quémard, A. In Vitro Inhibition of the Mycobacterium tuberculosis-Ketoacyl-Acyl Carrier Protein Reductase MabA by Isoniazid. Antimicrob. Agents Chemother., 2004, 48(1), 242-249.
102. Argyrou, A.; Vetting, M.W.; Aladegbami, B.; Blanchard, J.S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol., 2006, 13(5), 408-413.
103. Wimpenny, J.W. Effect of isoniazid on biosynthesis in Mycobacterium tuberculosis var. bovis BCG. J. Gen. Microbiol., 1967, 47(3), 379-388.
104. Wang, F.; Jain, P.; Gulten, G.; Liu, Z.; Feng, Y.; Ganesula, K.; Motiwala, A.S.; Ioerger, T.R.; Alland, D.; Vilcheze, C.; Jacobs, W.R., Jr.; Sacchettini, J.C. Mycobacterium tuberculosis Dihydrofolate Reductase Is Not a Target Relevant to the Antitubercular Activity of Isoniazid. Antimicrob. Agents Chemother., 2010, 54(9), 3776-3782.
105. Krishna, C.R.; Murti. In J.W. Corcoran and F.E. Hahn. Antibiotics, Ed.: North Holland : Springer Verlag, 1975; Vol. 3, p 623.
106. Devi, B.G.; Ramakrishnan, T.; Gopinathan, K.P. Proc. Indian Acad. Sci. B., 1974, 80, 240.
107. Youatt, J. Metabolism of isoniazid by Mycobacterium tuberculosis BCG with reference to current theories of the mode of action. Am. Rev. Tuberc., 1958, 78(5), 806-809.
108. Youatt, J. The Formation of 4-Pyridine Methanol from Isonicotinic Acid Hydrazide (Isoniazid) by Mycobacteria. Aust. J. Chem., 1961, 14(2), 308-311.
109. Youatt, J. The metabolism of isoniazid and pyridine aldehydes by Mycobacteria. Aust. J. Exp. Biol., 1962, 40, 191-196.
110. Krüger-Thiemer, E. Isonicotinic acid hypothesis of the antituberculous action of isoniazid. Am. Rev. Tuberc., 1958, 77(2), 364-367.
111. Kumar, A.; Farhana, A.; Guidry, L.; Saini, V.; Hondalus, M.; Steyn, A.J.C. Redox homeostasis in mycobacteria: the key to tuberculosis control? Expert Rev. Mol. Med., 2011, 13, e39.
112. Vandal, O.H.; Pierini, L.M.; Schnappinger, D.; Nathan, C.F.; Ehrt, S. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat. Med., 2008, 14(8), 849-854.
113. Zatman, L.J.; Kaplan, N.O.; Colowick, S.P.; Ciotti, M.M. The isolation and properties of the isonicotinic acid hydrazide analogue of diphosphopyridine nucleotide. J. Biol. Chem., 1954, 209(2), 467-484.
114. Kahn, V.; Blum, J.J. ATP-independent nicotinic acid mononucleotide pyrophosphorylase of Astasia longa. Biochim. Biophys. Acta, 1967, 146(1), 305-308.
115. Kahn, V.; Blum, J.J. Studies of nicotinic acid metabolism in Astasia longa. I. Incorporation of nicotinic acid into pyridine derivatives in exponentially growing and in synchronized cultures. J. Biol. Chem., 1968, 243(7), 1441-1447.
116. Kahn, V.; Blum, J.J. Studies of nicotinic acid metabolism in Astasia longa. II. Pathway and regulation of nicotinamide adenine dinucleotide biosynthesis in cell-free preparations. J. Biol. Chem., 1968, 243(7), 1448-1456.
117. Youatt, J. Pigments produced by Mycobacteria on exposure to isoniazid. 2. Aust. J. Exp. Biol. Med. Sci., 1962, 40, 197-200.
118. Youatt, J.; Tham, S.H. An enzyme system of Mycobacterium tuberculosis that reacts specifically with isoniazid. I. Am. Rev. Resp. Dis., 1969, 100(1), 25-30.
119. Devi, B.G.; Ramakrishnan, T.; Gopinathan, K.P. Enzymic interaction between isoniazid and nicotinamide-adenine dinucleotide. Biochem. J., 1972, 128(1), 63.
120. Nguyen, M.; Claparols, C.; Bernadou, J.; Meunier, B. A Fast and Efficient Metal-Mediated Oxidation of Isoniazid and Identification of Isoniazid-NAD(H) Adducts. ChemBioChem, 2001, 2(12), 877-883.
121. Broussy, S.; Coppel, Y.; Nguyen, M.; Bernadou, J.; Meunier, B. NMR Characterization of Hemiamidal Isoniazid-NAD(H) Adducts as Possible Inhibitors of InhA Reductase of Mycobacterium tuberculosis. Chem. Eur. J., 2003, 9(9), 2034-2038.